Weekly Dose 02
The Science Was There All Along
The science wasn’t wrong. It got stopped. This week, the record gets a little straighter.
WHAT’S HAPPENING WITH PSYCHEDELICS
🔬 One Dose of Psilocybin Beat Eight Weeks of Nicotine Patches
A randomized trial published this week found that a single high dose of psilocybin — combined with 13 weeks of talk therapy — was significantly more effective at helping smokers quit than nicotine patches worn for eight to ten weeks. The trial involved 82 adult smokers with no psychiatric conditions.
Nicotine patches work by replacing the drug while your brain slowly relearns to live without it. Psilocybin appears to do something different — a single session that shifts how the brain relates to the habit altogether. It’s the same logic being applied to depression and PTSD, now applied to one of the hardest addictions to break.
🏛️ The 1971 Ban Was Never Really About the Science
A new study published in Contemporary Drug Problems analyzed the United Nations decision to globally prohibit psychedelics in 1971 and found it was driven primarily by political ideology and media panic — not by evidence of medical harm. The researchers argue that current international drug law may need to be reexamined from the ground up.
In 1971, the same year psychedelics were banned, researchers were actively publishing promising results on LSD and psilocybin for depression, addiction, and end-of-life anxiety. That research didn’t fail — it got stopped. The 50-year gap between then and now isn’t a story of science catching up. It’s a story of science being interrupted.
🧠 A Minnesota Veteran Told Lawmakers Psilocybin Kept Him Alive. The Committee Advanced the Bill.
A Minnesota House committee moved forward this week on a bill to establish a supervised psilocybin therapy pilot program for adults with qualifying medical conditions. The hearing featured testimony from Army veteran Stefan Egan — five deployments, a suicide attempt, and then illicit access to psilocybin therapy that he credits with saving his life. “Without that access I wouldn’t be here,” he told the committee.
Minnesota would join a growing list of states moving toward supervised psilocybin access. The bill’s bipartisan co-sponsorship signals something broader: veteran testimony has become one of the most effective arguments in any statehouse, cutting through political divides in a way that clinical trial data rarely does.
Minnesota House of Representatives →
🏛️ New York Wants a Psilocybin Program for 10,000 Veterans — Then Plans to Shut It Down
A bill introduced in the New York State Assembly would create a supervised psilocybin therapy pilot program for veterans and first responders, with capacity for up to 10,000 patients. It includes an unusual self-termination clause: funding ends automatically if the federal government approves psilocybin for medical use.
New York’s legislature is explicitly betting that federal approval is coming — and building a program designed to hand off to it when it does. That’s not hedging. That’s planning.
UNDER THE MICROSCOPE
The Science Was Already There
The story most people tell about psychedelics goes like this: in the 1960s, LSD escaped the lab and became a symbol of counterculture chaos. Governments panicked, banned everything, and science went dark for fifty years. Now, finally, researchers are picking up where they left off.
It’s a tidy story. It’s also missing something important.
A new analysis published in Contemporary Drug Problems looked closely at the 1971 United Nations Convention on Psychotropic Substances — the international treaty that made psychedelics illegal in most of the world overnight — and found that the decision had almost nothing to do with medical evidence. There were no large-scale studies showing harm. No public health crisis triggered by psilocybin. No scientific consensus that these substances were uniquely dangerous. What there was: political pressure, moral panic, and a cultural moment in which psychedelics had become inseparable from protest movements, draft resistance, and a generation that governments on both sides of the Cold War found threatening.
At the moment of the ban, researchers at institutions like Johns Hopkins and Harvard had already published promising results on LSD and psilocybin for depression, addiction, and the anxiety of dying. That work wasn’t discredited — it simply stopped being possible. Funding dried up. Institutional approval became unreachable. A generation of researchers moved on to other questions.
This matters because it changes the frame. The psychedelic renaissance isn’t science finally catching up to a promising idea. It’s science resuming a conversation that was forcibly ended — and doing so with fifty years of better tools, better imaging technology, and a much clearer understanding of how the brain actually works.
The interruption wasn’t neutral. We don’t know what treatments might exist today if the research had continued. We don’t know how many people might have been helped. What we do know is that the decision to stop wasn’t made by scientists.
It was made by politicians.
And the decision to start again is being made the same way.
DOSE OF THE WEEK
📖 Making Psychedelics into Medicines — Tehseen Noorani, a Durham University anthropologist who spent years inside clinical trials, asks an uncomfortable question: what if turning psychedelics into FDA-approved pharmaceuticals actually destroys the thing that makes them work? A short, free academic paper with a longer shadow.
Next week: cognitive liberty, drug policy, and why the case for psychedelics might have nothing to do with medicine or science.
Stay curious. — DOSED